MedTrace Logo

Hydroxychloroquine in Outpatient Adults With COVID-19

NCT04333654 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-09-23

No results posted yet for this study

Summary

Primary Objective:

To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COVID-19

Secondary Objectives:

* To assess the effect of hydroxychloroquine versus placebo on clinical signs and symptoms and progression of disease in outpatient adults with COVID-19
* To assess the safety and tolerability of hydroxychloroquine in outpatient adults with COVID-19

Conditions

  • Coronavirus Infection

Interventions

DRUG

Hydroxychloroquine SAR321068

Pharmaceutical form:Tablet Route of administration: Oral

DRUG

Placebo

Pharmaceutical form:Tablet Route of administration: Oral

Sponsors & Collaborators

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-12
Primary Completion
2020-05-26
Completion
2020-05-26
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04333654 on ClinicalTrials.gov